Compare
Qiagen N.V. vs Bio-Techne Corp vs Tarsus Pharmaceuticals, Inc. vs Immunocore Holdings plc
| Latest fiscal year | Qiagen N.V. QGEN | Bio-Techne Corp TECH | Tarsus Pharmaceuticals, Inc. TARS | Immunocore Holdings plc IMCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.09B | $1.22B | $451.36M | $400.02M |
| Revenue growth (YoY) | +5.7% | -0.4% | +146.7% | +29.0% |
| Gross margin | 62.2% | 65.8% | n/a | n/a |
| Operating margin | 22.3% | 20.7% | -15.7% | -11.3% |
| Net margin | 20.3% | 15.0% | -14.7% | -8.9% |
| Net income | $424.88M | $181.86M | -$66.42M | -$35.51M |
| EPS (Diluted) | $1.94 | $1.16 | -$1.59 | -$0.71 |
| Operating cash flow | $654.33M | $292.07M | -$12.45M | -$10.71M |
| Free cash flow | $453.28M | $263.22M | -$22.31M | -$15.05M |
| Cash & equivalents | $839.00M | $264.71M | $183.64M | $467.71M |
| Total assets | $6.28B | $2.59B | $562.16M | $1.07B |
| Total liabilities | n/a | n/a | $218.73M | $686.24M |
| Shareholders' equity | $3.78B | $2.11B | $343.43M | $381.03M |
| Return on year-end equity | 11.2% | 8.6% | -19.3% | -9.3% |
| Shares outstanding | n/a | 156.10M | 42.55M | 50.69M |
Revenue, most recent five fiscal years
| Fiscal year | Qiagen N.V. | Bio-Techne Corp | Tarsus Pharmaceuticals, Inc. | Immunocore Holdings plc |
|---|---|---|---|---|
| Latest | $2.09B Ended 2025-12-31 | $1.22B Ended 2026-06-30 | $451.36M Ended 2025-12-31 | $400.02M Ended 2025-12-31 |
| 1 year earlier | $1.98B Ended 2024-12-31 | $1.22B Ended 2025-06-30 | $182.95M Ended 2024-12-31 | $310.20M Ended 2024-12-31 |
| 2 years earlier | $1.97B Ended 2023-12-31 | $1.16B Ended 2024-06-30 | $17.45M Ended 2023-12-31 | $249.43M Ended 2023-12-31 |
| 3 years earlier | $2.14B Ended 2022-12-31 | $1.14B Ended 2023-06-30 | $25.82M Ended 2022-12-31 | $174.36M Ended 2022-12-31 |
| 4 years earlier | $2.25B Ended 2021-12-31 | $1.11B Ended 2022-06-30 | $57.03M Ended 2021-12-31 | $36.48M Ended 2021-12-31 |